SHTDF OTC
Sinopharm Group Co. Ltd.
1W: -10.1%
1M: -13.0%
3M: -12.2%
YTD: -28.1%
1Y: -16.9%
3Y: -28.9%
5Y: -19.4%
$1.87
+0.04 (+2.41%)
Weekly Expected Move ±12.4%
$1
$2
$2
$2
$2
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Income Trends
Revenue
$560.3B
-4.1% ▼
5Y CAGR: +4.2%
Gross Profit
$40.2B
-9.3% ▼
5Y CAGR: -0.1%
Operating Income
$16.2B
+0.3% ▲
5Y CAGR: -1.8%
Net Income
$7.0B
-1.1% ▼
5Y CAGR: -0.6%
EPS (Diluted)
$2.24
-0.9% ▼
5Y CAGR: -0.6%
EBITDA
$20.4B
+1.2% ▲
5Y CAGR: -2.0%
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $521.1B | $552.1B | $596.6B | $584.5B | $560.3B |
| YoY Growth | +14.2% | +6.0% | +8.0% | -2.0% | -4.1% |
| Cost of Revenue | $477.0B | $504.7B | $548.1B | $540.3B | $520.2B |
| Gross Profit | $44.1B | $47.4B | $48.5B | $44.3B | $40.2B |
| Gross Margin | 8.5% | 8.6% | 8.1% | 7.6% | 7.2% |
| R&D Expenses | $0 | $0 | $0 | $0 | $0 |
| SG&A Expenses | $23.2B | $24.9B | $26.1B | $25.6B | $23.9B |
| Operating Expenses | $24.3B | $26.8B | $28.3B | $28.1B | $23.9B |
| Operating Income | $19.7B | $20.6B | $20.2B | $16.2B | $16.2B |
| Operating Margin | 3.8% | 3.7% | 3.4% | 2.8% | 2.9% |
| Interest Expense | $3.8B | $3.5B | $3.0B | $2.7B | $2.4B |
| Income Before Tax | $17.0B | $18.6B | $19.5B | $14.0B | $14.4B |
| Tax Expense | $3.9B | $4.2B | $4.5B | $3.6B | $3.9B |
| Net Income | $7.8B | $8.5B | $9.1B | $7.0B | $7.0B |
| Net Margin | 1.5% | 1.5% | 1.5% | 1.2% | 1.2% |
| EPS (Diluted) | $2.49 | $2.73 | $2.90 | $2.26 | $2.24 |
| EBITDA | $24.7B | $26.2B | $26.9B | $20.2B | $20.4B |
| Shares Outstanding | 3.11B | 3.12B | 3.12B | 3.12B | 3.12B |